Location History:
- Joensuu, FI (2018)
- Espoo, FI (2023)
Company Filing History:
Years Active: 2018-2023
Title: **Innovator Spotlight: Janne Jänis from Joensuu, Finland**
Introduction
Janne Jänis is a notable inventor based in Joensuu, Finland, who has made significant contributions to the field of immunotherapy. With a portfolio of two patents, he focuses on developing hypoallergenic polypeptides aimed at reducing allergic reactions in individuals sensitive to environmental allergens.
Latest Patents
Jänis's latest inventions include innovative solutions for horse and birch pollen allergies. His first patent, titled “Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy,” introduces specific modified Equ c 1 polypeptides designed as hypoallergens. This invention allows for the desensitization of individuals allergic to horses, reducing histamine release from basophils, thereby providing a safer immunotherapy option.
His second patent, simply referred to as “Hypoallergen,” presents mutant Bet v 1 proteins which serve as hypoallergens useful for desensitization against birch pollen allergies. This invention also encompasses vaccine formulations that include these polypeptides, outlining effective methods of vaccination to combat birch pollen allergy.
Career Highlights
Janne Jänis plays a pivotal role in the research and development initiatives at Desentum Oy. The company focuses on innovative solutions to treat allergies through advanced therapeutic applications. His work not only addresses immediate healthcare challenges but also contributes to long-term advancements in allergy treatment.
Collaborations
Jänis collaborates closely with fellow professionals Kristiina Takkinen and Marja-Leena Laukkanen, leveraging their collective expertise to enhance the efficacy of their innovations. Their teamwork embodies the spirit of collaboration vital for pushing the boundaries of current allergy therapies.
Conclusion
With a growing number of patents and ongoing research, Janne Jänis stands out as an influential figure in the realm of allergy immunotherapy. His dedication to creating hypoallergenic solutions has the potential to significantly improve the quality of life for individuals with allergies, reinforcing the importance of innovation in medical science.